secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0000950170-23-010609
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics reports positive BDC-1001 Phase 1 data; advances to Phase 2; cash $192.8M
--------------------------------------------------------------------------------

- BDC-1001 elicited objective responses including partial responses and stable disease across multiple HER2+ solid tumors as monotherapy and with nivolumab.
- Phase 2 program to start in 2023: two studies in breast, colorectal, endometrial, and gastroesophageal cancers.
- Entered clinical supply agreement with Roche for pertuzumab (Perjeta) to combine with BDC-1001 in breast cancer.
- Cash, cash equivalents, and marketable securities of $192.8M as of Dec 31, 2022, expected to fund operations through 2025.
- Full-year 2022 collaboration revenue $5.7M; R&D expenses $73.1M; loss from operations $90.3M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/0000950170-23-010609-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017023010609/bolt-20230329.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010609

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer